AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19338146 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) post-treated group
Number of subjects: 133
Study 19338146 — intervention group
Group type: COMPARATOR
Intervention: Shenfu Injection (SFI)
Number of subjects: 133
Study 16738348 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy
Number of subjects: 0
Study 16145898 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragali injection
Number of subjects: 60
Study 9065192 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal group (individualized education program)
Number of subjects: 1275
Study 9065192 — intervention group
Group type: COMPARATOR
Intervention: Document group (pamphlet detailing benefits of vaginal birth after cesarean)
Number of subjects: 1275
Study 8311029 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session parenting intervention program
Number of subjects: 70
Study 8311029 — intervention group
Group type: COMPARATOR
Intervention: wait-list condition
Number of subjects: 70
Study 3015809 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g) given within 5 min of amitriptyline (75 mg) dose
Number of subjects: 6
Study 3015809 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g followed by 12.5 g at 6-h intervals)
Number of subjects: 6
Study 3015809 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine pH acidification to 4
Number of subjects: 6
Study 30851620 — intervention group
Group type: EXPERIMENTAL
Intervention: HaRT-A
Number of subjects: 168
Study 30851620 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 168
Study 28425307 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.2% combined with fentanyl 20μg (F/R-group, n=31)
Number of subjects: 62
Study 28425307 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine 0.2% (R-group, n=31)
Number of subjects: 62
Study 28425307 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.2% combined with fentanyl 20μg (F/R-group)
Number of subjects: 62
Study 28425307 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine 0.2% (R-group)
Number of subjects: 62
Study 25239553 — intervention group
Group type: EXPERIMENTAL
Intervention: GI Mentor simulator
Number of subjects: 27
Study 25239553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both simulators (GI Mentor and Kyoto)
Number of subjects: 27
Study 25239553 — intervention group
Group type: COMPARATOR
Intervention: Kyoto simulator
Number of subjects: 27
Study 23321224 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dexamethasone
Number of subjects: 165
Study 23321224 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 165
Study 23321224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose powder)
Number of subjects: 165
Study 21077943 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat plus L‐carnitine
Number of subjects: 258
Study 21077943 — intervention group
Group type: COMPARATOR
Intervention: Orlistat alone
Number of subjects: 258
Study 19380188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealing system (BVSS)
Number of subjects: 90
Study 19380188 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture ligature
Number of subjects: 90
Study 16963828 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanesthetic ketamine infusion (0.5 mg/kg/h)
Number of subjects: 58
Study 16963828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 58
Study 15146395 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled studies (RCTs)
Number of subjects: 0
Study 15146395 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic studies
Number of subjects: 0
Study 11392465 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 8
Study 11392465 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Number of subjects: 8
Study 11392465 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg
Number of subjects: 8
Study 11392465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9589227 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1 g b.i.d. for 12 weeks
Number of subjects: 33
Study 9589227 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin at baseline dosage (1-2.5 g) for 12 weeks
Number of subjects: 33
Study 9589227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both studies (n = 33)
Number of subjects: 33
Study 9589227 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 33
Study 8181589 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Number of subjects: 0
Study 2548553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 12
Study 2548553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 12
Study 2548553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 20 mg
Number of subjects: 12
Study 2548553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2548553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 12
Study 780059 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (125 mg to 200 mg daily)
Number of subjects: 39
Study 780059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 780059 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 39
Study 28449972 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (prophylactic)
Number of subjects: 0
Study 28449972 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (therapeutic)
Number of subjects: 0
Study 28449972 — intervention group
Group type: COMPARATOR
Intervention: No paracetamol
Number of subjects: 0
Study 26028261 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated self-care intervention (education and counseling on combined HF and DM self-care with follow-up home visit and telephone counseling)
Number of subjects: 134
Study 26028261 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard HF and DM educational brochures with follow-up telephone contact)
Number of subjects: 134
Study 24156702 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (300 IU/kg intravenously after anesthetic induction)
Number of subjects: 98
Study 24156702 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline equivalent volume)
Number of subjects: 98
Study 21050700 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stocking system (Sigvaris Postoperative Kit; 23 to 32 mmHg at the ankle)
Number of subjects: 60
Study 21050700 — intervention group
Group type: COMPARATOR
Intervention: Standard stretch bandages
Number of subjects: 60
Study 21050700 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stocking system (Sigvaris Postoperative Kit)
Number of subjects: 60
Study 18501431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (9 g every 8h)
Number of subjects: 28
Study 18501431 — intervention group
Group type: COMPARATOR
Intervention: Colistin (3 MIU every 8h)
Number of subjects: 28
Study 16543097 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach (Pippa)
Number of subjects: 80
Study 16543097 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach (Winnie)
Number of subjects: 80
Study 15189625 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal exposure to a source
Number of subjects: 0
Study 15189625 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit exposure to a source
Number of subjects: 0
Study 15189625 — intervention group
Group type: COMPARATOR
Intervention: No exposure to a source
Number of subjects: 0
Study 11099714 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 1600 mg t.i.d.
Number of subjects: 563
Study 11099714 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 200 mg t.i.d.
Number of subjects: 563
Study 9663835 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 15 mg daily
Number of subjects: 103
Study 9663835 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg daily
Number of subjects: 103
Study 9663835 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole (both doses)
Number of subjects: 103
Study 8230148 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive Intervention (EI)
Number of subjects: 85
Study 8230148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate Intervention (AI)
Number of subjects: 85
Study 8230148 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Intervention (LI)
Number of subjects: 85
Study 8230148 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 85
Study 3786999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-finding trials
Number of subjects: 0
Study 3786999 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 29978223 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS
Number of subjects: 64
Study 29978223 — intervention group
Group type: COMPARATOR
Intervention: Non-POCUS
Number of subjects: 64
Study 27680411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine-enhanced liver magnetic resonance (MR) after transcatheter arterial chemoembolization (TACE)
Number of subjects: 45
Study 27680411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine-enhanced liver magnetic resonance (MR)
Number of subjects: 45
Study 24768595 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational session, clinician reminders, and individualized feedback
Number of subjects: 6
Study 24768595 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6
Study 24247995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation intervention (specific details not provided)
Number of subjects: 111
Study 20085546 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 280
Study 20085546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (RO2.0)
Number of subjects: 280
Study 20085546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (RO7.5)
Number of subjects: 280
Study 20085546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (BU2.5)
Number of subjects: 280
Study 20085546 — intervention group
Group type: EXPERIMENTAL
Intervention: All local anesthetics (RO2.0, RO7.5, BU2.5)
Number of subjects: 280
Study 18230021 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative evidence (personal account)
Number of subjects: 118
Study 18230021 — intervention group
Group type: COMPARATOR
Intervention: Statistical evidence (abstract prevalence data)
Number of subjects: 118
Study 18230021 — intervention group
Group type: COMPARATOR
Intervention: Mere assertion of increased risk
Number of subjects: 118
Study 18230021 — intervention group
Group type: COMPARATOR
Intervention: No risk information
Number of subjects: 118
Study 16628140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg orally twice per day for 3 days)
Number of subjects: 57
Study 16628140 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (2.5 mg and 1 mg intravenously)
Number of subjects: 57
Study 12556655 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 0
Study 12556655 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 0
Study 12556655 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 0
Study 12556655 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 0
Study 10953181 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrographic seizures (ESz) in neonates
Number of subjects: 68
Study 10953181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ESz)
Number of subjects: 68
Study 10953181 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of infants with asphyxia and ESz
Number of subjects: 68
Study 9219144 — intervention group
Group type: EXPERIMENTAL
Intervention: Active zones (Shenmen, Liver, Lung, and Sympathetic)
Number of subjects: 34
Study 9219144 — intervention group
Group type: COMPARATOR
Intervention: Control zones (located on the ear helix)
Number of subjects: 34
Study 9219144 — intervention group
Group type: EXPERIMENTAL
Intervention: Needles inserted into points of low electrical resistance in one ear and high electrical resistance in the other
Number of subjects: 34
Study 1486974 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticosteroid, budesonide 400 micrograms b.i.d.
Number of subjects: 0
Study 1486974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3721055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine (0.3 mg)
Number of subjects: 60
Study 3721055 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular combination of buprenorphine (0.3 mg)/naloxone (0.2 mg)
Number of subjects: 60
Study 31615892 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitalist managers
Number of subjects: 268239
Study 31615892 — intervention group
Group type: COMPARATOR
Intervention: Workers without a capitalist class advantage
Number of subjects: 268239
Study 29959929 — intervention group
Group type: EXPERIMENTAL
Intervention: Video presentation during physician counseling
Number of subjects: 120
Study 29959929 — intervention group
Group type: COMPARATOR
Intervention: Standard physician counseling (control arm)
Number of subjects: 120
Study 27169564 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg tablets
Number of subjects: 0
Study 27169564 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg tablets
Number of subjects: 0
Study 27169564 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg tablets
Number of subjects: 0
Study 27169564 — intervention group
Group type: COMPARATOR
Intervention: Olaparib 300 mg and 400 mg tablets
Number of subjects: 0
Study 25236873 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest triglycerides/HDL-C ratio quintile
Number of subjects: 3680
Study 25236873 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest total cholesterol/HDL-C ratio quintile
Number of subjects: 3680
Study 23250168 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal bracket + LED cured
Number of subjects: 60
Study 23250168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic bracket + LED cured
Number of subjects: 60
Study 23250168 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal bracket + plasma arc cured
Number of subjects: 60
Study 23250168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic bracket + plasma arc cured
Number of subjects: 60
Study 20113414 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% lidocaine spray
Number of subjects: 13
Study 20113414 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine patch
Number of subjects: 13
Study 20113414 — intervention group
Group type: COMPARATOR
Intervention: no application (control)
Number of subjects: 13
Study 18677174 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 34
Study 18677174 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (8 mg)
Number of subjects: 34
Study 18677174 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 16816482 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vitamin D3 therapy
Number of subjects: 0
Study 16816482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Active vitamin D3 and bisphosphonates
Number of subjects: 0
Study 16816482 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates
Number of subjects: 0
Study 12496225 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin
Number of subjects: 0
Study 12496225 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Control)
Number of subjects: 0
Study 9952390 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose ivermectin
Number of subjects: 40
Study 9952390 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ivermectin
Number of subjects: 40
Study 9952390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8603281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 20
Study 8603281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8603281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 50 mg
Number of subjects: 20
Study 8603281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 20
Study 2337571 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% eutectic mixture of lignocaine (100 mg) and prilocaine (100 mg) plus emulsifier (EMLA)
Number of subjects: 0
Study 2337571 — intervention group
Group type: COMPARATOR
Intervention: 10% lignocaine spray (200 mg)
Number of subjects: 0
Study 79707 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 207
Study 79707 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance plethysmography
Number of subjects: 207
Study 79707 — intervention group
Group type: COMPARATOR
Intervention: Venography
Number of subjects: 207
Study 31902129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring Exercise
Number of subjects: 259
Study 31902129 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 259
Study 31107396 — intervention group
Group type: EXPERIMENTAL
Intervention: Values affirmation
Number of subjects: 237
Study 31107396 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting affirmation
Number of subjects: 237
Study 31107396 — intervention group
Group type: COMPARATOR
Intervention: Control (no affirmation)
Number of subjects: 237
Study 28446764 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombination hot regions
Number of subjects: 0
Study 28446764 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of genes and DNA transposons
Number of subjects: 0
Study 28446764 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of long terminal repeat retrotransposons
Number of subjects: 0
Study 28446764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-mapped recombination hot regions
Number of subjects: 0
Study 28446764 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution genotyping of five randomly selected regions
Number of subjects: 0
Study 26001948 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate 5 mg intravenous infusion
Number of subjects: 2001
Study 26001948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2001
Study 23900920 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO)
Number of subjects: 36
Study 23900920 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 36
Study 20602013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10/66 caregiver intervention
Number of subjects: 58
Study 20602013 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 19122264 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 19122264 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (extension of trial)
Number of subjects: 0
Study 16791013 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine/tenofovir DF
Number of subjects: 300
Study 15038632 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10780755 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful weaning trial
Number of subjects: 81
Study 10780755 — intervention group
Group type: COMPARATOR
Intervention: Failed weaning trial
Number of subjects: 81
Study 10780755 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold values for tidal volume and effective compliance
Number of subjects: 81
Study 10780755 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal inspiratory pressure (MIP), deltaPI/MIP, respiratory frequency/tidal volume, CROP
Number of subjects: 81
Study 10780755 — intervention group
Group type: EXPERIMENTAL
Intervention: deltaPI/MIP and CROP
Number of subjects: 81
Study 10780755 — intervention group
Group type: EXPERIMENTAL
Intervention: occluded inspiratory pressure swing/maximal inspiratory pressure and compliance, rate, oxygenation, pressure index (CROP)
Number of subjects: 81
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia with 20 mg of 1% lidocaine and maintained with 2% lidocaine through an epidural catheter (Group I)
Number of subjects: 38
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal plain 20 mg of 0.5% bupivacaine (Group II)
Number of subjects: 38
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial dose of plain 0.5% bupivacaine 3 ml (15 mg) with an incremental dose of 3 ml (15 mg) (Group III)
Number of subjects: 38
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of epidural catheter during surgery (Group II)
Number of subjects: 38
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of epidural catheter during surgery (Group III)
Number of subjects: 38
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose of anesthetic (Group I)
Number of subjects: 38
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose of anesthetic (Group II)
Number of subjects: 38
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose of anesthetic (Group III)
Number of subjects: 38
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial pressure drop (Group I)
Number of subjects: 38
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial pressure drop (Group II)
Number of subjects: 38
Study 9432896 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial pressure drop (Group III)
Number of subjects: 38
Study 7871065 — intervention group
Group type: EXPERIMENTAL
Intervention: Three IM morphine injections (18 mg/70 kg) spaced at 12-h intervals
Number of subjects: 10
Study 7871065 — intervention group
Group type: EXPERIMENTAL
Intervention: Three IM morphine injections (18 mg/70 kg) spaced at 24-h intervals
Number of subjects: 10